Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) – Investment analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Ekso Bionics in a research note issued on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.00 per share for the year, down from their previous forecast of $0.02. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ FY2027 earnings at $0.12 EPS and FY2029 earnings at $0.46 EPS.
A number of other brokerages have also recently commented on EKSO. StockNews.com began coverage on shares of Ekso Bionics in a research note on Monday. They issued a “hold” rating on the stock. Lake Street Capital lowered their target price on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday.
Ekso Bionics Stock Down 8.0 %
EKSO opened at $0.40 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. Ekso Bionics has a 12 month low of $0.37 and a 12 month high of $1.64. The stock has a market capitalization of $8.86 million, a P/E ratio of -0.62 and a beta of 1.46. The business has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.82.
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The company had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Recommended Stories
- Five stocks we like better than Ekso Bionics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Investing In Automotive Stocks
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Insider Trading – What You Need to Know
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.